Clinical Trial Update: Intravitreous Ranibizumab as Adjunctive Treatment for Trabeculectomy in Neovascular Glaucoma [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating intravitreous ranibizumab as an adjunctive treatment for trabeculectomy in neovascular glaucoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Glaucoma

Drugs mentioned

• Ranibizumab (ranibizumab)

Snippet

Sponsor: Siriraj Hospital | Conditions: Glaucoma, Neovascular | Phase 4 | Status: COMPLETED